Preclinical studies have shown that orally administered MEK inhibitors effectively suppress MAPK signaling and reduce the size of plexiform and sub-cNFs in NF1 mouse models (11–13). This evidence concerns the gene MAP2K7 and neurofibromatosis type 1.